European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-06-18

Hepatic and Cardiac Toxicity Systems modelling

Objetivo

HeCaToS aims at developing integrative in silico tools for predicting human liver and heart toxicity. The objective is to develop an integrated modeling framework, by combining advances in computational chemistry and systems toxicology, for modelling toxic perturbations in liver and heart across multiple scales. This framework will include vertical integrations of representations from drug(metabolite)-target interactions, through macromolecules/proteins, to (sub-)cellular functionalities and organ physiologies, and even the human whole-body level. In view of the importance of mitochondrial deregulations and of immunological dysfunctions associated with hepatic and cardiac drug-induced injuries, focus will be on these particular Adverse Outcome Pathways. Models will be populated with data from innovative in vitro 3D liver and heart assays challenged with prototypical hepato- or cardiotoxicants; data will be generated by advanced molecular and functional analytical techniques retrieving information on key (sub-)cellular toxic evens. For validating perturbed AOPs in vitro in appropriate human investigations, case studies on patients with liver injuries or cardiomyopathies due to adverse drug effects, will be developed, and biopsies will be subjected to similar analyses. Existing ChEMBL and diXa data infrastructures will be advanced for data gathering, storing and integrated statistical analysis. Model performance in toxicity prediction will be assessed by comparing in silico predictions with experimental results across a multitude of read-out parameters, which in turn will suggest additional experiments for further validating predictions. HeCaToS, organized as a private-public partnership, will generate major socioeconomic impact because it will develop better chemical safety tests leading to safer drugs, but also industrial chemicals, and cosmetics, thereby improving patient and consumer health, and sustaining EU’s industrial competitiveness.

Ámbito científico

Programa(s)

Tema(s)

Convocatoria de propuestas

FP7-HEALTH-2013-INNOVATION-1
Consulte otros proyectos de esta convocatoria

Régimen de financiación

CP-IP - Large-scale integrating project

Coordinador

UNIVERSITEIT MAASTRICHT
Aportación de la UE
€ 2 673 569,00
Dirección
MINDERBROEDERSBERG 4
6200 MD Maastricht
Países Bajos

Ver en el mapa
Región
Zuid-Nederland Limburg (NL) Zuid-Limburg
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
René Reijnders (Mr.)
Enlaces
Coste total
Sin datos

Participantes (13)

Compartir esta página

Descargar

Última actualización: 7 Noviembre 2016

Mi folleto

Permalink: https://cordis.europa.eu/project/id/602156/es

European Union, 2024